U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C12H22O11
Molecular Weight 342.2965
Optical Activity UNSPECIFIED
Defined Stereocenters 10 / 10
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of .ALPHA.-LACTOSE

SMILES

[H][C@@]2(O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O)O[C@H](CO)[C@H](O)[C@H](O)[C@H]2O

InChI

InChIKey=GUBGYTABKSRVRQ-XLOQQCSPSA-N
InChI=1S/C12H22O11/c13-1-3-5(15)6(16)9(19)12(22-3)23-10-4(2-14)21-11(20)8(18)7(10)17/h3-20H,1-2H2/t3-,4-,5+,6+,7-,8-,9-,10-,11+,12+/m1/s1

HIDE SMILES / InChI

Molecular Formula C12H22O11
Molecular Weight 342.2965
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 10 / 10
E/Z Centers 0
Optical Activity UNSPECIFIED

Lactose is the most important carbohydrate in the milk of most species. Its biosynthesis takes place in the mammary gland. The molecular structures of α- and β -lactose differ in the orientation of a hydrogen- and a hydroxyl group on carbon atom no.1 in the glucose moiety. Both forms change into one another continuously. At room temperature, the equilibrium results in a ratio of about 40% α-lactose and 60% β-lactose. The fact that two forms of lactose exist which differ in molecular structure has profound effects on various properties of lactose such as crystallization behavior, crystal morphology, solid-state properties, and solubility. The intestine does not actively absorb lactose unless it is split into its two-monosaccharide components, i.e. glucose and galactose. This hydrolysis of lactose is affected by the enzyme lactase, which is produced by the epithelium cells in the brush-border of the small intestine. Thus, the capacity of mammals to digest lactose is dependent on the lactase activity in the intestine. The maximum activity of the enzyme occurs shortly after birth and declines during the weaning period, after which it remains at a relatively constant level. Genetically determined factors governing residual lactase activity also exist. Individuals having low lactase activity are called lactose malabsorbers. Lactose intolerance is a condition in which people have symptoms due to the decreased ability to digest lactose. The principal symptom of lactose intolerance is an adverse reaction to products containing lactose (primarily milk), including abdominal bloating and cramps, flatulence, diarrhea, nausea, borborygmi, and vomiting (particularly in adolescents). These appear one-half to two hours after consumption.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P09848
Gene ID: 3938.0
Gene Symbol: LCT
Target Organism: Homo sapiens (Human)
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
PubMed

PubMed

TitleDatePubMed
Identification and synthesis of a novel 15 kDa beta-galactoside-binding lectin in human leukocytes.
1992 Aug
Method to recover a lipophilic drug from hydroxypropyl methylcellulose matrix tablets.
2001 Jun 9
Effects of droplet size and type of binder on the agglomerate growth mechanisms by melt agglomeration in a fluidised bed.
2002 Aug
Signal and noise in bridging PCR.
2002 Jul 18
Clickhaler dry powder inhaler: focussed in vitro proof of principle evaluation of a new chemical entity for asthma.
2002 Jun 4
Continuous twin screw extrusion for the wet granulation of lactose.
2002 Jun 4
Investigation of excipient type and level on drug release from controlled release tablets containing HPMC.
2002 May
A method for obtaining equilibrium tautomeric mixtures of reducing sugars via glycosylamines using nonaqueous media.
2002 May 13
A recombinant Saccharomyces cerevisiae strain for efficient conversion of lactose in salted and unsalted cheese whey into ethanol.
2002 Oct
Characterization of a surface modified dry powder inhalation carrier prepared by "particle smoothing".
2002 Oct
The evaluation of the rheological properties of lactose/microcrystalline cellulose and water mixtures by controlled stress rheometry and the relationship to the production of spherical pellets by extrusion/spheronization.
2002 Oct
Dissolution kinetics of single crystals of alpha-lactose monohydrate.
2002 Oct
Lactose modifications enhance its drug performance in the novel multiple dose Taifun DPI.
2002 Sep
An efficient synthesis of novel carbocyclic nucleosides with use of ring-closing metathesis from D-lactose.
2002 Sep 20
Carbon and nitrogen substrate utilization by archival Salmonella typhimurium LT2 cells.
2002 Sep 8
Development of agglomerated directly compressible diluent consisting of brittle and ductile materials.
2003
Influence of inverse gas chromatography measurement conditions on surface energy parameters of lactose monohydrate.
2003 Apr 30
Synthesis of novel apionucleosides: a short and concise synthesis of 2-deoxyapio-L-furanosyl acetate from D-lactose.
2003 Apr 4
Cryopreservation of spermatozoa from closed colonies, and inbred, spontaneous mutant, and transgenic strains of rats.
2003 Dec
Further investigations into the use of high sensitivity differential scanning calorimetry as a means of predicting drug-excipient interactions.
2003 Feb 18
Influence of physico-chemical carrier properties on the in vitro aerosol deposition from interactive mixtures.
2003 Feb 18
Carotenoid production by lactoso-negative yeasts co-cultivated with lactic acid bacteria in whey ultrafiltrate.
2003 Jul-Aug
The preparation of agglomerates containing solid dispersions of diazepam by melt agglomeration in a high shear mixer.
2003 Jun 18
Effects of excipients on hydrate formation in wet masses containing theophylline.
2003 Mar
Nutritional requirements of Pochonia chlamydospora and ARF18, fungal parasites of nematode eggs.
2003 May
The influence of carrier and drug morphology on drug delivery from dry powder formulations.
2003 May 12
The relationship between granule growth mechanism, amount of liquid binder added and properties of the wet powder mass determined using a split bed shear tester.
2003 May 12
A novel technique for imaging film coating defects in the film-core interface and surface of coated tablets.
2003 Nov
Physiological studies of Escherichia coli strain MG1655: growth defects and apparent cross-regulation of gene expression.
2003 Sep
Glucose transport in lactation.
2004
The 3D model: explaining densification and deformation mechanisms by using 3D parameter plots.
2004 Apr
Energy-based analysis of milling alpha-lactose monohydrate.
2004 Apr
Synthesis and hemolytic activity of some hederagenin diglycosides.
2004 Aug
Characterization and taste-masking evaluation of acetaminophen granules: comparison between different preparation methods in a high-shear mixer.
2004 Feb
Alternative sugars as potential carriers for dry powder inhalations.
2004 Feb 11
Demographic and health-related correlates of herbal and specialty supplement use.
2004 Jan
Visualization of the crystallization of lactose from the amorphous state.
2004 Jan
Moisture-induced surface crystallization of spray-dried amorphous lactose particles studied by atomic force microscopy.
2004 Jan
Single-step granulation/tabletting of different grades of lactose: a comparison with high shear granulation and compression.
2004 Jul
Influence of cellulose ether polymers on ketoprofen release from hydrophilic matrix tablets.
2004 Jul
Use of whey ultrafiltrate as a substrate for production of carotenoids by the yeast Rhodotorula rubra.
2004 Mar
The influence of carrier roughness on adhesion, content uniformity and the in vitro deposition of terbutaline sulphate from dry powder inhalers.
2004 May 4
Compaction of crystallographic forms of pharmaceutical granular lactoses. I. Compressibility.
2004 Nov
Investigations into the use of pregelatinised starch to develop powder-filled hard capsules.
2004 Nov 5
Approaches to determine the enthalpy of crystallisation, and amorphous content, of lactose from isothermal calorimetric data.
2004 Oct 13
The cohesive-adhesive balances in dry powder inhaler formulations I: Direct quantification by atomic force microscopy.
2004 Sep
Comparison of torque measurements and near-infrared spectroscopy in characterization of a wet granulation process.
2004 Sep
Blockage of Galectin-receptor Interactions by α-lactose Exacerbates Plasmodium berghei-induced Pulmonary Immunopathology.
2016 Aug 24
Lactase Non-persistence and Lactose Intolerance.
2017 May
Lactase non-persistent genotype distribution in Italy.
2017 Sep

Sample Use Guides

presence lactose in the food
Route of Administration: Oral
In Vitro Use Guide
There was evaluated the capability of colonic bacteria to ferment lactose and the ability of L. acidophilus to modify lactose fermentation by the colonic microflora in vitro. An anaerobic continuous culture was established and inoculated with fresh samples of human feces. Lactose infusion was maintained at 25 g/d and pH at 6.7. L. acidophilus strain LA-1 (1.5 x 10(10) cells) was introduced into the fermenter on d 0 or added daily on d 0 through 4. The control was the continuous culture without the addition of lactobacilli. Rapid adaptation of colonic bacteria to lactose occurred within 1-2 d, with a significant decrease in lactose concentration and increase in beta-galactosidase activity, and lactose concentrations fell below 3 mmol/L by d 7.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:43:20 UTC 2023
Edited
by admin
on Fri Dec 15 15:43:20 UTC 2023
Record UNII
MJF4JAT10B
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
.ALPHA.-LACTOSE
Common Name English
O-.BETA.-D-GALACTOPYRANOSYL-(1->4)-.ALPHA.-D-GLUCOPYRANOSE
Common Name English
.ALPHA.-D-GLUCOPYRANOSE, 4-O-.BETA.-D-GALACTOPYRANOSYL-
Systematic Name English
ALPHA LACTOSE
Common Name English
Code System Code Type Description
PUBCHEM
84571
Created by admin on Fri Dec 15 15:43:20 UTC 2023 , Edited by admin on Fri Dec 15 15:43:20 UTC 2023
PRIMARY
CHEBI
36219
Created by admin on Fri Dec 15 15:43:20 UTC 2023 , Edited by admin on Fri Dec 15 15:43:20 UTC 2023
PRIMARY
ECHA (EC/EINECS)
238-691-8
Created by admin on Fri Dec 15 15:43:20 UTC 2023 , Edited by admin on Fri Dec 15 15:43:20 UTC 2023
PRIMARY
CAS
14641-93-1
Created by admin on Fri Dec 15 15:43:20 UTC 2023 , Edited by admin on Fri Dec 15 15:43:20 UTC 2023
PRIMARY
DAILYMED
MJF4JAT10B
Created by admin on Fri Dec 15 15:43:20 UTC 2023 , Edited by admin on Fri Dec 15 15:43:20 UTC 2023
PRIMARY
RXCUI
2359362
Created by admin on Fri Dec 15 15:43:20 UTC 2023 , Edited by admin on Fri Dec 15 15:43:20 UTC 2023
PRIMARY
FDA UNII
MJF4JAT10B
Created by admin on Fri Dec 15 15:43:20 UTC 2023 , Edited by admin on Fri Dec 15 15:43:20 UTC 2023
PRIMARY
EPA CompTox
DTXSID50873004
Created by admin on Fri Dec 15 15:43:20 UTC 2023 , Edited by admin on Fri Dec 15 15:43:20 UTC 2023
PRIMARY